nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—Lisinopril—systemic scleroderma	0.441	1	CrCtD
Nateglinide—Enalapril—Captopril—systemic scleroderma	0.0973	0.336	CrCrCtD
Nateglinide—UGT1A9—Mycophenolic acid—systemic scleroderma	0.0468	0.214	CbGbCtD
Nateglinide—Cilazapril—Lisinopril—systemic scleroderma	0.0342	0.118	CrCrCtD
Nateglinide—Spirapril—Lisinopril—systemic scleroderma	0.0342	0.118	CrCrCtD
Nateglinide—Trandolapril—Lisinopril—systemic scleroderma	0.0321	0.111	CrCrCtD
Nateglinide—Ramipril—Lisinopril—systemic scleroderma	0.0321	0.111	CrCrCtD
Nateglinide—Enalapril—Lisinopril—systemic scleroderma	0.0321	0.111	CrCrCtD
Nateglinide—SLC15A1—Lisinopril—systemic scleroderma	0.0293	0.134	CbGbCtD
Nateglinide—Aspartame—Lisinopril—systemic scleroderma	0.0272	0.094	CrCrCtD
Nateglinide—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.0261	0.12	CbGbCtD
Nateglinide—SLC15A1—Captopril—systemic scleroderma	0.0219	0.1	CbGbCtD
Nateglinide—SLC16A1—Methotrexate—systemic scleroderma	0.0182	0.0835	CbGbCtD
Nateglinide—SLC22A6—Captopril—systemic scleroderma	0.0121	0.0553	CbGbCtD
Nateglinide—ALB—Captopril—systemic scleroderma	0.0103	0.0471	CbGbCtD
Nateglinide—ABCC4—Methotrexate—systemic scleroderma	0.00877	0.0401	CbGbCtD
Nateglinide—ALB—Mycophenolate mofetil—systemic scleroderma	0.0081	0.0371	CbGbCtD
Nateglinide—CYP2C9—Leflunomide—systemic scleroderma	0.00707	0.0324	CbGbCtD
Nateglinide—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.00651	0.0298	CbGbCtD
Nateglinide—ALB—Prednisone—systemic scleroderma	0.00648	0.0297	CbGbCtD
Nateglinide—CYP2D6—Captopril—systemic scleroderma	0.00507	0.0232	CbGbCtD
Nateglinide—SLC22A6—Methotrexate—systemic scleroderma	0.00382	0.0175	CbGbCtD
Nateglinide—ALB—Methotrexate—systemic scleroderma	0.00325	0.0149	CbGbCtD
Nateglinide—CYP2C9—cardial valve—systemic scleroderma	0.00291	0.213	CbGeAlD
Nateglinide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00254	0.0116	CbGbCtD
Nateglinide—PPARG—dermis—systemic scleroderma	0.00206	0.151	CbGeAlD
Nateglinide—CYP3A4—Prednisone—systemic scleroderma	0.00203	0.00929	CbGbCtD
Nateglinide—PPARG—artery—systemic scleroderma	0.000744	0.0545	CbGeAlD
Nateglinide—PPARG—endothelium—systemic scleroderma	0.000629	0.046	CbGeAlD
Nateglinide—PPARG—blood vessel—systemic scleroderma	0.00058	0.0425	CbGeAlD
Nateglinide—UGT1A9—digestive system—systemic scleroderma	0.000437	0.032	CbGeAlD
Nateglinide—PTGS1—artery—systemic scleroderma	0.000398	0.0291	CbGeAlD
Nateglinide—Arthropathy—Mycophenolic acid—systemic scleroderma	0.000384	0.0105	CcSEcCtD
Nateglinide—Polyuria—Captopril—systemic scleroderma	0.000367	0.01	CcSEcCtD
Nateglinide—ABCC8—smooth muscle tissue—systemic scleroderma	0.000356	0.0261	CbGeAlD
Nateglinide—Arthropathy—Lisinopril—systemic scleroderma	0.000346	0.00946	CcSEcCtD
Nateglinide—Spirapril—ACE—systemic scleroderma	0.000343	0.194	CrCbGaD
Nateglinide—PTGS1—endothelium—systemic scleroderma	0.000336	0.0246	CbGeAlD
Nateglinide—Jaundice—Pentoxifylline—systemic scleroderma	0.000319	0.00874	CcSEcCtD
Nateglinide—Influenza—Mometasone—systemic scleroderma	0.000317	0.00868	CcSEcCtD
Nateglinide—Sweating—Pentoxifylline—systemic scleroderma	0.000314	0.0086	CcSEcCtD
Nateglinide—PTGS1—blood vessel—systemic scleroderma	0.00031	0.0227	CbGeAlD
Nateglinide—Hepatobiliary disease—Pentoxifylline—systemic scleroderma	0.00031	0.00848	CcSEcCtD
Nateglinide—Lisinopril—ACE—systemic scleroderma	0.000305	0.173	CrCbGaD
Nateglinide—Cilazapril—ACE—systemic scleroderma	0.000305	0.173	CrCbGaD
Nateglinide—Bronchitis—Mometasone—systemic scleroderma	0.000305	0.00835	CcSEcCtD
Nateglinide—Arthropathy—Mycophenolate mofetil—systemic scleroderma	0.000303	0.00829	CcSEcCtD
Nateglinide—PPARG—connective tissue—systemic scleroderma	0.000297	0.0218	CbGeAlD
Nateglinide—Trandolapril—ACE—systemic scleroderma	0.000296	0.167	CrCbGaD
Nateglinide—Ramipril—ACE—systemic scleroderma	0.000296	0.167	CrCbGaD
Nateglinide—Upper respiratory tract infection—Mometasone—systemic scleroderma	0.000295	0.00807	CcSEcCtD
Nateglinide—Hepatic enzyme increased—Mycophenolate mofetil—systemic scleroderma	0.000291	0.00797	CcSEcCtD
Nateglinide—KCNJ11—tendon—systemic scleroderma	0.000291	0.0213	CbGeAlD
Nateglinide—Injury—Mycophenolic acid—systemic scleroderma	0.000276	0.00755	CcSEcCtD
Nateglinide—PPARG—smooth muscle tissue—systemic scleroderma	0.000272	0.0199	CbGeAlD
Nateglinide—SLC15A1—digestive system—systemic scleroderma	0.000269	0.0197	CbGeAlD
Nateglinide—PPARG—skin of body—systemic scleroderma	0.000268	0.0197	CbGeAlD
Nateglinide—Thirst—Mycophenolic acid—systemic scleroderma	0.000266	0.00729	CcSEcCtD
Nateglinide—Immune system disorder—Pentoxifylline—systemic scleroderma	0.000266	0.00727	CcSEcCtD
Nateglinide—Osteoarthritis—Leflunomide—systemic scleroderma	0.000266	0.00727	CcSEcCtD
Nateglinide—Hypoglycaemia—Mycophenolic acid—systemic scleroderma	0.00026	0.00711	CcSEcCtD
Nateglinide—SLC16A1—digestive system—systemic scleroderma	0.000256	0.0187	CbGeAlD
Nateglinide—Osteoarthritis—Mycophenolic acid—systemic scleroderma	0.000253	0.00694	CcSEcCtD
Nateglinide—Injury—Lisinopril—systemic scleroderma	0.000248	0.0068	CcSEcCtD
Nateglinide—Back pain—Pentoxifylline—systemic scleroderma	0.000248	0.00678	CcSEcCtD
Nateglinide—SLC16A1—tendon—systemic scleroderma	0.000244	0.0178	CbGeAlD
Nateglinide—Jaundice—Captopril—systemic scleroderma	0.000242	0.00663	CcSEcCtD
Nateglinide—Tremor—Pentoxifylline—systemic scleroderma	0.00024	0.00657	CcSEcCtD
Nateglinide—Hypoglycaemia—Lisinopril—systemic scleroderma	0.000234	0.0064	CcSEcCtD
Nateglinide—Influenza—Leflunomide—systemic scleroderma	0.000229	0.00628	CcSEcCtD
Nateglinide—Immune system disorder—Mometasone—systemic scleroderma	0.000229	0.00628	CcSEcCtD
Nateglinide—Osteoarthritis—Lisinopril—systemic scleroderma	0.000228	0.00625	CcSEcCtD
Nateglinide—Palpitations—Pentoxifylline—systemic scleroderma	0.000226	0.0062	CcSEcCtD
Nateglinide—Enalapril—ACE—systemic scleroderma	0.000224	0.127	CrCbGaD
Nateglinide—Sweating increased—Leflunomide—systemic scleroderma	0.000224	0.00612	CcSEcCtD
Nateglinide—Bronchitis—Leflunomide—systemic scleroderma	0.000221	0.00604	CcSEcCtD
Nateglinide—Influenza—Mycophenolic acid—systemic scleroderma	0.000219	0.00599	CcSEcCtD
Nateglinide—Injury—Mycophenolate mofetil—systemic scleroderma	0.000217	0.00596	CcSEcCtD
Nateglinide—PPARG—digestive system—systemic scleroderma	0.000215	0.0157	CbGeAlD
Nateglinide—SLC16A1—lung—systemic scleroderma	0.000214	0.0157	CbGeAlD
Nateglinide—Back pain—Mometasone—systemic scleroderma	0.000214	0.00585	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Leflunomide—systemic scleroderma	0.000213	0.00584	CcSEcCtD
Nateglinide—Erythema multiforme—Captopril—systemic scleroderma	0.000211	0.00577	CcSEcCtD
Nateglinide—Bronchitis—Mycophenolic acid—systemic scleroderma	0.000211	0.00577	CcSEcCtD
Nateglinide—Thirst—Mycophenolate mofetil—systemic scleroderma	0.00021	0.00575	CcSEcCtD
Nateglinide—Arthropathy—Prednisone—systemic scleroderma	0.000205	0.00562	CcSEcCtD
Nateglinide—Hepatobiliary disease—Azathioprine—systemic scleroderma	0.000205	0.00561	CcSEcCtD
Nateglinide—Hypoglycaemia—Mycophenolate mofetil—systemic scleroderma	0.000205	0.00561	CcSEcCtD
Nateglinide—PPARG—tendon—systemic scleroderma	0.000204	0.015	CbGeAlD
Nateglinide—Upper respiratory tract infection—Mycophenolic acid—systemic scleroderma	0.000203	0.00557	CcSEcCtD
Nateglinide—Hyperhidrosis—Pentoxifylline—systemic scleroderma	0.000202	0.00553	CcSEcCtD
Nateglinide—Neuropathy peripheral—Leflunomide—systemic scleroderma	0.000201	0.00549	CcSEcCtD
Nateglinide—Osteoarthritis—Mycophenolate mofetil—systemic scleroderma	0.0002	0.00547	CcSEcCtD
Nateglinide—Jaundice—Leflunomide—systemic scleroderma	0.000199	0.00546	CcSEcCtD
Nateglinide—Influenza—Lisinopril—systemic scleroderma	0.000197	0.0054	CcSEcCtD
Nateglinide—ABCC4—digestive system—systemic scleroderma	0.000195	0.0143	CbGeAlD
Nateglinide—Hepatobiliary disease—Leflunomide—systemic scleroderma	0.000194	0.0053	CcSEcCtD
Nateglinide—Cough—Mometasone—systemic scleroderma	0.000193	0.00528	CcSEcCtD
Nateglinide—Sweating increased—Lisinopril—systemic scleroderma	0.000192	0.00526	CcSEcCtD
Nateglinide—ORM1—lung—systemic scleroderma	0.000192	0.014	CbGeAlD
Nateglinide—Neuropathy peripheral—Mycophenolic acid—systemic scleroderma	0.000191	0.00524	CcSEcCtD
Nateglinide—Jaundice—Mycophenolic acid—systemic scleroderma	0.00019	0.00521	CcSEcCtD
Nateglinide—Bronchitis—Lisinopril—systemic scleroderma	0.00019	0.00519	CcSEcCtD
Nateglinide—Sweating—Mycophenolic acid—systemic scleroderma	0.000187	0.00512	CcSEcCtD
Nateglinide—ABCC4—tendon—systemic scleroderma	0.000186	0.0136	CbGeAlD
Nateglinide—Hepatobiliary disease—Mycophenolic acid—systemic scleroderma	0.000185	0.00506	CcSEcCtD
Nateglinide—Dyspepsia—Pentoxifylline—systemic scleroderma	0.000184	0.00504	CcSEcCtD
Nateglinide—Erythema multiforme—Azathioprine—systemic scleroderma	0.000184	0.00504	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Lisinopril—systemic scleroderma	0.000183	0.00502	CcSEcCtD
Nateglinide—Oedema peripheral—Leflunomide—systemic scleroderma	0.000181	0.00496	CcSEcCtD
Nateglinide—PPARG—lung—systemic scleroderma	0.000179	0.0131	CbGeAlD
Nateglinide—Immune system disorder—Azathioprine—systemic scleroderma	0.000176	0.00481	CcSEcCtD
Nateglinide—Erythema multiforme—Leflunomide—systemic scleroderma	0.000174	0.00476	CcSEcCtD
Nateglinide—Influenza—Mycophenolate mofetil—systemic scleroderma	0.000173	0.00473	CcSEcCtD
Nateglinide—Oedema peripheral—Mycophenolic acid—systemic scleroderma	0.000173	0.00473	CcSEcCtD
Nateglinide—Neuropathy peripheral—Lisinopril—systemic scleroderma	0.000172	0.00472	CcSEcCtD
Nateglinide—Palpitations—Captopril—systemic scleroderma	0.000171	0.00469	CcSEcCtD
Nateglinide—Jaundice—Lisinopril—systemic scleroderma	0.000171	0.00469	CcSEcCtD
Nateglinide—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.000171	0.00468	CcSEcCtD
Nateglinide—Cough—Captopril—systemic scleroderma	0.000169	0.00464	CcSEcCtD
Nateglinide—Sweating—Lisinopril—systemic scleroderma	0.000169	0.00462	CcSEcCtD
Nateglinide—Hepatobiliary disease—Lisinopril—systemic scleroderma	0.000166	0.00455	CcSEcCtD
Nateglinide—Bronchitis—Mycophenolate mofetil—systemic scleroderma	0.000166	0.00455	CcSEcCtD
Nateglinide—Urticaria—Pentoxifylline—systemic scleroderma	0.000166	0.00455	CcSEcCtD
Nateglinide—Immune system disorder—Leflunomide—systemic scleroderma	0.000166	0.00454	CcSEcCtD
Nateglinide—Abdominal pain—Pentoxifylline—systemic scleroderma	0.000165	0.00452	CcSEcCtD
Nateglinide—Hepatic enzyme increased—Methotrexate—systemic scleroderma	0.000165	0.00452	CcSEcCtD
Nateglinide—ABCC4—lung—systemic scleroderma	0.000163	0.0119	CbGeAlD
Nateglinide—Malnutrition—Leflunomide—systemic scleroderma	0.00016	0.00438	CcSEcCtD
Nateglinide—PTGS1—connective tissue—systemic scleroderma	0.000159	0.0116	CbGeAlD
Nateglinide—Dyspepsia—Mometasone—systemic scleroderma	0.000159	0.00435	CcSEcCtD
Nateglinide—Oedema peripheral—Lisinopril—systemic scleroderma	0.000155	0.00426	CcSEcCtD
Nateglinide—Fatigue—Mometasone—systemic scleroderma	0.000155	0.00426	CcSEcCtD
Nateglinide—Back pain—Leflunomide—systemic scleroderma	0.000155	0.00424	CcSEcCtD
Nateglinide—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000154	0.00422	CcSEcCtD
Nateglinide—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000153	0.00418	CcSEcCtD
Nateglinide—Neuropathy peripheral—Mycophenolate mofetil—systemic scleroderma	0.000151	0.00413	CcSEcCtD
Nateglinide—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.00015	0.00411	CcSEcCtD
Nateglinide—Asthenia—Pentoxifylline—systemic scleroderma	0.00015	0.0041	CcSEcCtD
Nateglinide—Erythema multiforme—Lisinopril—systemic scleroderma	0.000149	0.00409	CcSEcCtD
Nateglinide—Pruritus—Pentoxifylline—systemic scleroderma	0.000148	0.00405	CcSEcCtD
Nateglinide—Sweating—Mycophenolate mofetil—systemic scleroderma	0.000148	0.00404	CcSEcCtD
Nateglinide—Back pain—Mycophenolic acid—systemic scleroderma	0.000148	0.00404	CcSEcCtD
Nateglinide—Injury—Prednisone—systemic scleroderma	0.000147	0.00404	CcSEcCtD
Nateglinide—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000147	0.00404	CcSEcCtD
Nateglinide—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.000146	0.00399	CcSEcCtD
Nateglinide—PTGS1—smooth muscle tissue—systemic scleroderma	0.000145	0.0106	CbGeAlD
Nateglinide—Increased appetite—Prednisone—systemic scleroderma	0.000144	0.00395	CcSEcCtD
Nateglinide—PTGS1—skin of body—systemic scleroderma	0.000144	0.0105	CbGeAlD
Nateglinide—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000143	0.00391	CcSEcCtD
Nateglinide—Tremor—Mycophenolic acid—systemic scleroderma	0.000143	0.00391	CcSEcCtD
Nateglinide—Abdominal pain—Mometasone—systemic scleroderma	0.000143	0.0039	CcSEcCtD
Nateglinide—Palpitations—Leflunomide—systemic scleroderma	0.000141	0.00387	CcSEcCtD
Nateglinide—Urine output increased—Methotrexate—systemic scleroderma	0.000141	0.00386	CcSEcCtD
Nateglinide—SLC15A2—lung—systemic scleroderma	0.00014	0.0103	CbGeAlD
Nateglinide—Cough—Leflunomide—systemic scleroderma	0.00014	0.00382	CcSEcCtD
Nateglinide—Dyspepsia—Captopril—systemic scleroderma	0.000139	0.00382	CcSEcCtD
Nateglinide—Dizziness—Pentoxifylline—systemic scleroderma	0.000138	0.00378	CcSEcCtD
Nateglinide—Malnutrition—Lisinopril—systemic scleroderma	0.000137	0.00376	CcSEcCtD
Nateglinide—Fatigue—Captopril—systemic scleroderma	0.000137	0.00374	CcSEcCtD
Nateglinide—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.000136	0.00373	CcSEcCtD
Nateglinide—Osteoarthritis—Prednisone—systemic scleroderma	0.000136	0.00371	CcSEcCtD
Nateglinide—Palpitations—Mycophenolic acid—systemic scleroderma	0.000135	0.00369	CcSEcCtD
Nateglinide—Cough—Mycophenolic acid—systemic scleroderma	0.000133	0.00365	CcSEcCtD
Nateglinide—Back pain—Lisinopril—systemic scleroderma	0.000133	0.00364	CcSEcCtD
Nateglinide—Vomiting—Pentoxifylline—systemic scleroderma	0.000133	0.00364	CcSEcCtD
Nateglinide—Rash—Pentoxifylline—systemic scleroderma	0.000132	0.00361	CcSEcCtD
Nateglinide—Dermatitis—Pentoxifylline—systemic scleroderma	0.000132	0.0036	CcSEcCtD
Nateglinide—Gastrointestinal pain—Captopril—systemic scleroderma	0.000129	0.00355	CcSEcCtD
Nateglinide—Asthenia—Mometasone—systemic scleroderma	0.000129	0.00354	CcSEcCtD
Nateglinide—Polyuria—Methotrexate—systemic scleroderma	0.000129	0.00353	CcSEcCtD
Nateglinide—Tremor—Lisinopril—systemic scleroderma	0.000129	0.00353	CcSEcCtD
Nateglinide—CYP3A5—digestive system—systemic scleroderma	0.000128	0.00936	CbGeAlD
Nateglinide—Pruritus—Mometasone—systemic scleroderma	0.000128	0.00349	CcSEcCtD
Nateglinide—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000126	0.00345	CcSEcCtD
Nateglinide—CYP2C9—digestive system—systemic scleroderma	0.000126	0.00921	CbGeAlD
Nateglinide—Abdominal pain—Captopril—systemic scleroderma	0.000125	0.00343	CcSEcCtD
Nateglinide—Nausea—Pentoxifylline—systemic scleroderma	0.000124	0.0034	CcSEcCtD
Nateglinide—Diarrhoea—Mometasone—systemic scleroderma	0.000123	0.00338	CcSEcCtD
Nateglinide—Palpitations—Lisinopril—systemic scleroderma	0.000121	0.00332	CcSEcCtD
Nateglinide—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00012	0.0033	CcSEcCtD
Nateglinide—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00012	0.0033	CcSEcCtD
Nateglinide—Cough—Lisinopril—systemic scleroderma	0.00012	0.00328	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000119	0.00327	CcSEcCtD
Nateglinide—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000116	0.00319	CcSEcCtD
Nateglinide—Dyspepsia—Leflunomide—systemic scleroderma	0.000115	0.00315	CcSEcCtD
Nateglinide—PTGS1—digestive system—systemic scleroderma	0.000115	0.00841	CbGeAlD
Nateglinide—Vomiting—Mometasone—systemic scleroderma	0.000115	0.00314	CcSEcCtD
Nateglinide—Sweating increased—Prednisone—systemic scleroderma	0.000114	0.00312	CcSEcCtD
Nateglinide—Rash—Mometasone—systemic scleroderma	0.000114	0.00311	CcSEcCtD
Nateglinide—Asthenia—Captopril—systemic scleroderma	0.000114	0.00311	CcSEcCtD
Nateglinide—Dermatitis—Mometasone—systemic scleroderma	0.000114	0.00311	CcSEcCtD
Nateglinide—Osteoarthritis—Methotrexate—systemic scleroderma	0.000113	0.0031	CcSEcCtD
Nateglinide—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000113	0.00309	CcSEcCtD
Nateglinide—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000113	0.00309	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000113	0.00309	CcSEcCtD
Nateglinide—Fatigue—Leflunomide—systemic scleroderma	0.000113	0.00308	CcSEcCtD
Nateglinide—Pruritus—Captopril—systemic scleroderma	0.000112	0.00307	CcSEcCtD
Nateglinide—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00011	0.003	CcSEcCtD
Nateglinide—PTGS1—tendon—systemic scleroderma	0.000109	0.008	CbGeAlD
Nateglinide—Abdominal pain—Azathioprine—systemic scleroderma	0.000109	0.00299	CcSEcCtD
Nateglinide—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000108	0.00297	CcSEcCtD
Nateglinide—Diarrhoea—Captopril—systemic scleroderma	0.000108	0.00297	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000107	0.00294	CcSEcCtD
Nateglinide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000107	0.00294	CcSEcCtD
Nateglinide—Nausea—Mometasone—systemic scleroderma	0.000107	0.00293	CcSEcCtD
Nateglinide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000107	0.00292	CcSEcCtD
Nateglinide—CYP3A5—lung—systemic scleroderma	0.000107	0.00781	CbGeAlD
Nateglinide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000106	0.00291	CcSEcCtD
Nateglinide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000105	0.00288	CcSEcCtD
Nateglinide—Dizziness—Captopril—systemic scleroderma	0.000105	0.00287	CcSEcCtD
Nateglinide—Urticaria—Leflunomide—systemic scleroderma	0.000104	0.00284	CcSEcCtD
Nateglinide—Abdominal pain—Leflunomide—systemic scleroderma	0.000103	0.00282	CcSEcCtD
Nateglinide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000102	0.0028	CcSEcCtD
Nateglinide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000102	0.00279	CcSEcCtD
Nateglinide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000102	0.00279	CcSEcCtD
Nateglinide—Vomiting—Captopril—systemic scleroderma	0.000101	0.00276	CcSEcCtD
Nateglinide—Rash—Captopril—systemic scleroderma	9.98e-05	0.00273	CcSEcCtD
Nateglinide—Dermatitis—Captopril—systemic scleroderma	9.98e-05	0.00273	CcSEcCtD
Nateglinide—Dyspepsia—Lisinopril—systemic scleroderma	9.87e-05	0.0027	CcSEcCtD
Nateglinide—Abdominal pain—Mycophenolic acid—systemic scleroderma	9.84e-05	0.00269	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	9.68e-05	0.00265	CcSEcCtD
Nateglinide—Fatigue—Lisinopril—systemic scleroderma	9.67e-05	0.00265	CcSEcCtD
Nateglinide—Hypersensitivity—Leflunomide—systemic scleroderma	9.62e-05	0.00263	CcSEcCtD
Nateglinide—CYP3A4—digestive system—systemic scleroderma	9.59e-05	0.00702	CbGeAlD
Nateglinide—PTGS1—lung—systemic scleroderma	9.59e-05	0.00702	CbGeAlD
Nateglinide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	9.5e-05	0.0026	CcSEcCtD
Nateglinide—Diarrhoea—Azathioprine—systemic scleroderma	9.46e-05	0.00259	CcSEcCtD
Nateglinide—CYP2D6—digestive system—systemic scleroderma	9.44e-05	0.00691	CbGeAlD
Nateglinide—Nausea—Captopril—systemic scleroderma	9.41e-05	0.00258	CcSEcCtD
Nateglinide—Asthenia—Leflunomide—systemic scleroderma	9.36e-05	0.00256	CcSEcCtD
Nateglinide—Pruritus—Leflunomide—systemic scleroderma	9.23e-05	0.00253	CcSEcCtD
Nateglinide—Gastrointestinal pain—Lisinopril—systemic scleroderma	9.17e-05	0.00251	CcSEcCtD
Nateglinide—Dizziness—Azathioprine—systemic scleroderma	9.14e-05	0.0025	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	9.1e-05	0.00249	CcSEcCtD
Nateglinide—Asthenia—Mycophenolic acid—systemic scleroderma	8.93e-05	0.00245	CcSEcCtD
Nateglinide—Diarrhoea—Leflunomide—systemic scleroderma	8.93e-05	0.00245	CcSEcCtD
Nateglinide—Urticaria—Lisinopril—systemic scleroderma	8.91e-05	0.00244	CcSEcCtD
Nateglinide—Abdominal pain—Lisinopril—systemic scleroderma	8.86e-05	0.00243	CcSEcCtD
Nateglinide—Pruritus—Mycophenolic acid—systemic scleroderma	8.81e-05	0.00241	CcSEcCtD
Nateglinide—Vomiting—Azathioprine—systemic scleroderma	8.79e-05	0.00241	CcSEcCtD
Nateglinide—Rash—Azathioprine—systemic scleroderma	8.71e-05	0.00239	CcSEcCtD
Nateglinide—Dermatitis—Azathioprine—systemic scleroderma	8.71e-05	0.00238	CcSEcCtD
Nateglinide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	8.65e-05	0.00237	CcSEcCtD
Nateglinide—Dizziness—Leflunomide—systemic scleroderma	8.63e-05	0.00236	CcSEcCtD
Nateglinide—Diarrhoea—Mycophenolic acid—systemic scleroderma	8.52e-05	0.00233	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	8.48e-05	0.00232	CcSEcCtD
Nateglinide—Immune system disorder—Prednisone—systemic scleroderma	8.47e-05	0.00232	CcSEcCtD
Nateglinide—Sweating—Methotrexate—systemic scleroderma	8.37e-05	0.00229	CcSEcCtD
Nateglinide—Vomiting—Leflunomide—systemic scleroderma	8.3e-05	0.00227	CcSEcCtD
Nateglinide—Hypersensitivity—Lisinopril—systemic scleroderma	8.26e-05	0.00226	CcSEcCtD
Nateglinide—Hepatobiliary disease—Methotrexate—systemic scleroderma	8.25e-05	0.00226	CcSEcCtD
Nateglinide—Dizziness—Mycophenolic acid—systemic scleroderma	8.23e-05	0.00225	CcSEcCtD
Nateglinide—Rash—Leflunomide—systemic scleroderma	8.23e-05	0.00225	CcSEcCtD
Nateglinide—Dermatitis—Leflunomide—systemic scleroderma	8.22e-05	0.00225	CcSEcCtD
Nateglinide—Nausea—Azathioprine—systemic scleroderma	8.21e-05	0.00225	CcSEcCtD
Nateglinide—Malnutrition—Prednisone—systemic scleroderma	8.16e-05	0.00223	CcSEcCtD
Nateglinide—Asthenia—Lisinopril—systemic scleroderma	8.05e-05	0.0022	CcSEcCtD
Nateglinide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	8.03e-05	0.0022	CcSEcCtD
Nateglinide—Pruritus—Lisinopril—systemic scleroderma	7.93e-05	0.00217	CcSEcCtD
Nateglinide—Vomiting—Mycophenolic acid—systemic scleroderma	7.92e-05	0.00217	CcSEcCtD
Nateglinide—Rash—Mycophenolic acid—systemic scleroderma	7.85e-05	0.00215	CcSEcCtD
Nateglinide—Dermatitis—Mycophenolic acid—systemic scleroderma	7.84e-05	0.00215	CcSEcCtD
Nateglinide—Urticaria—Mycophenolate mofetil—systemic scleroderma	7.81e-05	0.00214	CcSEcCtD
Nateglinide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	7.77e-05	0.00213	CcSEcCtD
Nateglinide—Nausea—Leflunomide—systemic scleroderma	7.75e-05	0.00212	CcSEcCtD
Nateglinide—Diarrhoea—Lisinopril—systemic scleroderma	7.67e-05	0.0021	CcSEcCtD
Nateglinide—Dizziness—Lisinopril—systemic scleroderma	7.42e-05	0.00203	CcSEcCtD
Nateglinide—Erythema multiforme—Methotrexate—systemic scleroderma	7.41e-05	0.00203	CcSEcCtD
Nateglinide—Nausea—Mycophenolic acid—systemic scleroderma	7.4e-05	0.00202	CcSEcCtD
Nateglinide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	7.24e-05	0.00198	CcSEcCtD
Nateglinide—Vomiting—Lisinopril—systemic scleroderma	7.13e-05	0.00195	CcSEcCtD
Nateglinide—Immune system disorder—Methotrexate—systemic scleroderma	7.08e-05	0.00194	CcSEcCtD
Nateglinide—Rash—Lisinopril—systemic scleroderma	7.07e-05	0.00194	CcSEcCtD
Nateglinide—Dermatitis—Lisinopril—systemic scleroderma	7.06e-05	0.00193	CcSEcCtD
Nateglinide—Asthenia—Mycophenolate mofetil—systemic scleroderma	7.05e-05	0.00193	CcSEcCtD
Nateglinide—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.95e-05	0.0019	CcSEcCtD
Nateglinide—Malnutrition—Methotrexate—systemic scleroderma	6.82e-05	0.00187	CcSEcCtD
Nateglinide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.72e-05	0.00184	CcSEcCtD
Nateglinide—Nausea—Lisinopril—systemic scleroderma	6.66e-05	0.00182	CcSEcCtD
Nateglinide—Back pain—Methotrexate—systemic scleroderma	6.6e-05	0.00181	CcSEcCtD
Nateglinide—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.5e-05	0.00178	CcSEcCtD
Nateglinide—Hyperhidrosis—Prednisone—systemic scleroderma	6.44e-05	0.00176	CcSEcCtD
Nateglinide—Vomiting—Mycophenolate mofetil—systemic scleroderma	6.25e-05	0.00171	CcSEcCtD
Nateglinide—Rash—Mycophenolate mofetil—systemic scleroderma	6.2e-05	0.0017	CcSEcCtD
Nateglinide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	6.19e-05	0.00169	CcSEcCtD
Nateglinide—Cough—Methotrexate—systemic scleroderma	5.95e-05	0.00163	CcSEcCtD
Nateglinide—Dyspepsia—Prednisone—systemic scleroderma	5.86e-05	0.00161	CcSEcCtD
Nateglinide—Nausea—Mycophenolate mofetil—systemic scleroderma	5.84e-05	0.0016	CcSEcCtD
Nateglinide—Fatigue—Prednisone—systemic scleroderma	5.74e-05	0.00157	CcSEcCtD
Nateglinide—Gastrointestinal pain—Prednisone—systemic scleroderma	5.45e-05	0.00149	CcSEcCtD
Nateglinide—Hyperhidrosis—Methotrexate—systemic scleroderma	5.38e-05	0.00147	CcSEcCtD
Nateglinide—Urticaria—Prednisone—systemic scleroderma	5.29e-05	0.00145	CcSEcCtD
Nateglinide—Abdominal pain—Prednisone—systemic scleroderma	5.27e-05	0.00144	CcSEcCtD
Nateglinide—Hypersensitivity—Prednisone—systemic scleroderma	4.91e-05	0.00134	CcSEcCtD
Nateglinide—Dyspepsia—Methotrexate—systemic scleroderma	4.9e-05	0.00134	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.81e-05	0.00132	CcSEcCtD
Nateglinide—Fatigue—Methotrexate—systemic scleroderma	4.8e-05	0.00131	CcSEcCtD
Nateglinide—Asthenia—Prednisone—systemic scleroderma	4.78e-05	0.00131	CcSEcCtD
Nateglinide—Pruritus—Prednisone—systemic scleroderma	4.71e-05	0.00129	CcSEcCtD
Nateglinide—Diarrhoea—Prednisone—systemic scleroderma	4.56e-05	0.00125	CcSEcCtD
Nateglinide—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.55e-05	0.00125	CcSEcCtD
Nateglinide—Urticaria—Methotrexate—systemic scleroderma	4.42e-05	0.00121	CcSEcCtD
Nateglinide—Dizziness—Prednisone—systemic scleroderma	4.4e-05	0.00121	CcSEcCtD
Nateglinide—Abdominal pain—Methotrexate—systemic scleroderma	4.4e-05	0.0012	CcSEcCtD
Nateglinide—Vomiting—Prednisone—systemic scleroderma	4.23e-05	0.00116	CcSEcCtD
Nateglinide—Rash—Prednisone—systemic scleroderma	4.2e-05	0.00115	CcSEcCtD
Nateglinide—Dermatitis—Prednisone—systemic scleroderma	4.2e-05	0.00115	CcSEcCtD
Nateglinide—Hypersensitivity—Methotrexate—systemic scleroderma	4.1e-05	0.00112	CcSEcCtD
Nateglinide—Asthenia—Methotrexate—systemic scleroderma	3.99e-05	0.00109	CcSEcCtD
Nateglinide—Nausea—Prednisone—systemic scleroderma	3.96e-05	0.00108	CcSEcCtD
Nateglinide—Pruritus—Methotrexate—systemic scleroderma	3.94e-05	0.00108	CcSEcCtD
Nateglinide—Diarrhoea—Methotrexate—systemic scleroderma	3.81e-05	0.00104	CcSEcCtD
Nateglinide—Dizziness—Methotrexate—systemic scleroderma	3.68e-05	0.00101	CcSEcCtD
Nateglinide—Vomiting—Methotrexate—systemic scleroderma	3.54e-05	0.000969	CcSEcCtD
Nateglinide—Rash—Methotrexate—systemic scleroderma	3.51e-05	0.000961	CcSEcCtD
Nateglinide—Dermatitis—Methotrexate—systemic scleroderma	3.51e-05	0.00096	CcSEcCtD
Nateglinide—Nausea—Methotrexate—systemic scleroderma	3.31e-05	0.000905	CcSEcCtD
